Measuring fatigue in sarcoidosis: The Fatigue Assessment Scale (FAS)

Vries, Jolanda De; Michielsen, Helen J.; Heck, G.L. van; Drent, Marjolein

doi:10.1348/1359107041557048

Cited by 297 publications

(249 citation statements)

References 31 publications

Supporting

Mentioning

235

Contrasting

Unclassified

Order By: Relevance

“…Different effects of prednisolone have been previously documented in the literature. 25 According to Drent et al, 4 prednisolone may induce muscle weakness, leading to a collapse of upper airway muscles and therefore yielding fatigue. Whether this direct effect of prednisolone increases fatigue in patients with sarcoidosis or the higher activity of disease, which makes the treatment with prednisolone necessary, is not quite clear and should be considered in further investigations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors Associated With Fatigue in Sarcoidosis

Fleischer¹,

Hinz²,

Brähler³

et al. 2013

Respir Care

View full text Add to dashboard Cite

BACKGROUND: Fatigue is a frequent symptom of patients with sarcoidosis. The origin of fatigue associated with sarcoidosis is unclear. The aim of this study was to assess the impact of affected organs, medication, and comorbidity on fatigue related to sarcoidosis. METHOD: In collaboration with the German Sarcoidosis Society, a sample of 1,197 subjects diagnosed with sarcoidosis was examined. The participants completed a questionnaire that contained the Fatigue Assessment Scale and the Multidimensional Fatigue Inventory. RESULTS: In this study, muscles, bones, and nerves were most strongly associated with fatigue. Patients receiving prednisolone showed heightened fatigue levels. However, the association between the duration of prednisolone therapy and fatigue was weak. The concomitant diseases, pulmonary hypertension and sleep apnea, showed the greatest impact elevating fatigue (effect sizes d > 0.50). In the combined regression analysis, comorbidity was the most important predictor of fatigue. CONCLUSIONS: It is important to consider that multiple clinical factors, especially comorbidities, contribute to the high degrees of fatigue in sarcoidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…22,24 Initially developed by De Vries et al, 25 it is a well-validated and reliable scale. 22 The questionnaire consists of 2 subscales, 5 questions each on the physical and mental aspect of fatigue.…”

Section: Fasmentioning

confidence: 99%

Factors Associated With Fatigue in Sarcoidosis

Fleischer¹,

Hinz²,

Brähler³

et al. 2013

Respir Care

View full text Add to dashboard Cite

show abstract

“…An assessment of overall organ involvement, extrapulmonary physician organ severity tool (ePOST) [36], was performed at each visit, using all information available to the physician. Patients also completed several additional patient reported outcomes (PRO) questionnaires, including the 36-item short form health survey (SF-36) [37], the Fatigue Assessment Scale (FAS) [38], the sarcoidosis assessment tool (SAT) [39], and a patient global assessment (PGA) of overall wellbeing on a visual analogue scale. An Independent Data Monitoring Committee reviewed all available data after the 15th randomised patient had completed the week-16 visit and, periodically, thereafter.…”

Section: Methodsmentioning

confidence: 99%

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

et al. 2014

Self Cite

View full text Add to dashboard Cite

Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-a. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-a, respectively.Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (DFVC % pred) in the lung group. Major secondary end-points were: week 28 for DFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group).At week 16, no significant differences were observed in DFVC % pred with ustekinumab (-0.15, p50.13) or golimumab (1.15, p50.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups.Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points. @ERSpublicationsNeither ustekinumab nor golimumab demonstrated efficacy for the treatment of patients with pulmonary sarcoidosis

show abstract

“…Although these two aspects of fatigue are represented in the questionnaire, the FAS was unidimensional when completed by a Dutch working population and a representative group of the general population [19,20], as well as in sarcoidosis patients [10,21]. The unidimensional structure indicates that the FAS total score should be used.…”

Section: Methodsmentioning

confidence: 99%

“…Scores on the FAS range from 10 to 50. The psychometric properties are good in Dutch healthy individuals and sarcoidosis patients [10,20,21]. In the BC patients, Cronbach's alpha internal consistency was 0.88, in the BBP group 0.92.…”

Section: Methodsmentioning

confidence: 99%

Personality and fatigue in patients with benign or malignant breast disease

Michielsen

Steeg

Roukema

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

Goals of work The aim of the study was to examine the role of five general personality traits in fatigue in a group of patients with breast cancer (BC) and a group with benign breast problems (BBP). Materials and methods Of the 304 participating women, 127 patients had BC and 177 BBP. A fatigue scale was completed before diagnosis and 1, 3, and 6 months after diagnosis (benign patients) or surgical treatment (BC patients). A personality questionnaire (NEO-FFI) and a depression scale (CES-D) were completed before diagnosis. Main results The BC group was less tired before diagnosis, more tired 1 month after diagnosis, and equally tired 3 and 6 months after diagnosis. In the total group, women were more tired over time when they were more neurotic, less agreeable, or more introverted. After controlling for depressive symptoms, demographics, and medical factors, baseline depressive symptoms (β=0.29, p<0.05), neuroticism (β=0.29, p<0.05), and extraversion (β=−0.25, p< 0.05) predicted fatigue 6 months later. After also including baseline fatigue, only neuroticism (β=0.22, p<0.05) and baseline fatigue (β=0.79, p<0.001) predicted fatigue.Conclusions Personality is more strongly related to fatigue than demographics, the diagnosis cancer, receiving cancer treatment, and baseline depressive symptoms and fatigue. When replicated, screening and treating women who are at risk to experience high levels of fatigue is recommended.

show abstract

Measuring fatigue in sarcoidosis: The Fatigue Assessment Scale (FAS)

Cited by 297 publications

References 31 publications

Factors Associated With Fatigue in Sarcoidosis

Factors Associated With Fatigue in Sarcoidosis

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

Personality and fatigue in patients with benign or malignant breast disease

Contact Info

Product

Resources

About